Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on October 9, 2007
JNCI Journal of the National Cancer Institute 2007 99(20):1510-1515; doi:10.1093/jnci/djm171
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow JNCI Podcast
Right arrow All Versions of this Article:
99/20/1510    most recent
djm171v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Etzioni, R. D.
Right arrow Articles by Thompson, I. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Etzioni, R. D.
Right arrow Articles by Thompson, I. M.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press.

COMMENTARY

Is Prostate-Specific Antigen Velocity Useful in Early Detection of Prostate Cancer? A Critical Appraisal of the Evidence

Ruth D. Etzioni, Donna P. Ankerst, Noel S. Weiss, Lurdes Y. T. Inoue, Ian M. Thompson

Affiliations of authors: Translational and Outcomes Research Group, Fred Hutchinson Cancer Research Center, Seattle, WA (RDE); University of Washington, Seattle, WA (NSW, LYTI); University of Texas Health Sciences Center at San Antonio, San Antonio, TX (DPA, IMT)

Correspondence to: Ruth D. Etzioni, PhD, Translational and Outcomes Research Group, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave North, M2-B230, PO Box 19024, Seattle, WA 98109 (e-mail: retzioni{at}fhcrc.org).

Prostate-specific antigen velocity (PSAV) is one of the oldest concepts in PSA screening, yet today it is one of the most controversial. Publication of a wide range of studies with different designs, study populations, and results has fueled uncertainty about the best way to use PSAV and confused the issue of its utility in the early detection setting. Studies of disease prognosis suggest that PSAV is strongly associated with lethal cancers. However, prospective screening trials find that PSAV is at best a weak predictor of high-risk disease. In this commentary, we synthesize and reconcile the evidence about the value of PSAV in the early detection setting. We review recent studies of PSAV and determine a set of statistical considerations that we believe to be critical in study evaluation and interpretation. We explain why the association between PSAV and disease-specific survival does not necessarily imply that PSAV will be a useful screening tool. In addition, we argue that the standard concept of PSAV—the absolute change in PSA per year—confuses disease aggressiveness with the interval from disease onset to detection. We therefore recommend that other methods be explored to incorporate information about PSA kinetics that could ultimately improve—and even transform—how we detect and treat prostate cancer.

Manuscript received March 30, 2007; revised July 26, 2007; accepted August 28, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

IN THIS ISSUE
J Natl Cancer Inst 2007 99: 1497. [Extract] [Full Text] [PDF]

PSA Velocity's Clinical Usefulness Remains Unclear
Liz Savage and Andrea Widener
J Natl Cancer Inst 2007 99: 1497. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 JCOHome page
A. V. D'Amico
Prostate-Specific Antigen (PSA) and PSA Velocity: Competitors or Collaborators in the Prediction of Curable and Clinically Significant Prostate Cancer
J. Clin. Oncol., February 20, 2008; 26(6): 823 - 824.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.